---
document_datetime: 2025-12-02 05:14:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/roctavian.html
document_name: roctavian.html
version: success
processing_time: 0.1101392
conversion_datetime: 2025-12-24 20:42:52.073104
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Roctavian

[RSS](/en/individual-human-medicine.xml/67591)

##### Authorised

This medicine is authorised for use in the European Union

valoctocogene roxaparvovec Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Roctavian](#news-on)
- [More information on Roctavian](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Roctavian is a medicine for treating severe haemophilia A, an inherited bleeding disorder caused by the lack of a clotting protein known as factor VIII. It is used in adults who do not have inhibitors (antibodies) against factor VIII and who have no antibodies against adeno-associated virus serotype 5 (AAV5).

Roctavian contains the active substance valoctocogene roxaparvovec and is a type of advanced therapy medicine called a 'gene therapy product'. This is a type of medicine that works by delivering genes into the body.

Haemophilia A is rare, and Roctavian was designated an 'orphan medicine' (a medicine used in rare diseases) on 21 March 2016. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/EU3161622](/en/medicines/human/orphan-designations/eu-3-16-1622) .

Expand section

Collapse section

## How is Roctavian used?

The medicine can only be obtained with a prescription and treatment should be started under supervision of a doctor experienced in the treatment of haemophilia or bleeding disorders. The medicine should be given in a facility equipped to promptly treat infusion-related reactions.

Roctavian is given as a single infusion (drip) into a vein over a number of hours. The dose depends on the patient's body weight. Patients may be given other medicines to reduce the risk of infusion-related reactions.

For more information about using Roctavian, see the package leaflet or contact your doctor or pharmacist.

## How does Roctavian work?

Roctavian is made of a virus (AAV5) that has been modified to contain the gene for factor VIII, which is lacking in patients with haemophilia A. After being given to the patient, the virus is expected to carry the factor VIII gene into the liver cells, enabling them to produce the missing factor VIII for a long period. This is expected to control the bleeding disorder.

The type of virus used in this medicine (adeno-associated virus) does not cause disease in humans.

## What benefits of Roctavian have been shown in studies?

A main study involving 134 adult male patients with severe haemophilia A found that Roctavian was effective at increasing the level of factor VIII activity and that this increase was sustained for at least 2 years. 104 weeks after receiving a single dose of the medicine, 75.4% of the patients had an average factor VIII activity level of at least 5 international units per decilitre (IU/dL), which is a measure of mild haemophilia. In addition, the yearly number of bleeding episodes decreased by 85.5% and the need for additional factor VIII replacement treatment dropped by 97.5%.

## What are the risks associated with Roctavian?

The most common side effects with Roctavian (which may affect more than 3 in 10 people) are increased levels of the liver enzymes alanine aminotransferase and aspartate aminotransferase (signs of possible liver problems), increased levels of the enzyme lactate dehydrogenase (sign of possible tissue damage), nausea (feeling sick) and headache. For the full list of side effects of Roctavian, see the package leaflet.

Roctavian must not be given to people who are hypersensitive (allergic) to any of its ingredients, or who have an active or chronic (long-term) infection that is not controlled by medicines or significant liver fibrosis or liver cirrhosis (scarring of the liver).

## Why is Roctavian authorised in the EU?

Patients with haemophilia A require lifelong treatment with one or more injections per week or month to replace or mimic the missing factor VIII. Roctavian has been shown to be effective at increasing the level of factor VIII activity in patients with haemophilia A, and this increase is sustained for at least 2 years. The European Medicines Agency also considered that, as Roctavian is given as a single infusion, it would reduce the treatment burden for patients with severe haemophilia A for at least 2 years. Although the long-term safety data are limited, the safety profile was considered acceptable.

Roctavian has been given 'conditional authorisation'. This means that the Agency decided that the benefits of Roctavian are greater than its risks, but the company will have to provide additional evidence after authorisation.

Conditional authorisation is granted on the basis of less comprehensive data than are normally required. It is granted for medicines that fulfil an unmet medical need to treat serious diseases and when the benefits of having them available earlier outweigh any risks associated with using the medicines while waiting for further evidence. Every year, the Agency will review any new information that becomes available until data become comprehensive and this overview will be updated as necessary.

## What information is still awaited for Roctavian?

Since Roctavian has been given conditional authorisation, the company that markets Roctavian will provide additional data from ongoing studies on the long-term safety and effectiveness of the medicine in patients with severe haemophilia A and will carry out a study on when to best start corticosteroid treatment in these patients to avoid liver problems. The company will also provide data from a registry of patients treated with Roctavian to study its long-term safety and effectiveness.

## What measures are being taken to ensure the safe and effective use of Roctavian?

The company that markets Roctavian will provide patients and healthcare professionals with educational material explaining the benefits, risks and uncertainties about the long-term effects of the medicine. Patients will also be given a patient card to inform healthcare professionals that they have received Roctavian to treat haemophilia A.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Roctavian have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Roctavian are continuously monitored. Suspected side effects reported with Roctavian are carefully evaluated and any necessary action taken to protect patients.

## Other information about Roctavian

Roctavian received a conditional marketing authorisation valid throughout the EU on 24 August 2022.

Roctavian : EPAR - Medicine Overview

Reference Number: EMA/654780/2022

English (EN) (119.43 KB - PDF)

**First published:** 06/09/2022

[View](/en/documents/overview/roctavian-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-704)

български (BG) (135.65 KB - PDF)

**First published:**

06/09/2022

[View](/bg/documents/overview/roctavian-epar-medicine-overview_bg.pdf)

español (ES) (109.02 KB - PDF)

**First published:**

06/09/2022

[View](/es/documents/overview/roctavian-epar-medicine-overview_es.pdf)

čeština (CS) (132.18 KB - PDF)

**First published:**

06/09/2022

[View](/cs/documents/overview/roctavian-epar-medicine-overview_cs.pdf)

dansk (DA) (108.08 KB - PDF)

**First published:**

06/09/2022

[View](/da/documents/overview/roctavian-epar-medicine-overview_da.pdf)

Deutsch (DE) (112.99 KB - PDF)

**First published:**

06/09/2022

[View](/de/documents/overview/roctavian-epar-medicine-overview_de.pdf)

eesti keel (ET) (96.29 KB - PDF)

**First published:**

06/09/2022

[View](/et/documents/overview/roctavian-epar-medicine-overview_et.pdf)

ελληνικά (EL) (134.86 KB - PDF)

**First published:**

06/09/2022

[View](/el/documents/overview/roctavian-epar-medicine-overview_el.pdf)

français (FR) (111.12 KB - PDF)

**First published:**

06/09/2022

[View](/fr/documents/overview/roctavian-epar-medicine-overview_fr.pdf)

hrvatski (HR) (132.04 KB - PDF)

**First published:**

06/09/2022

[View](/hr/documents/overview/roctavian-epar-medicine-overview_hr.pdf)

italiano (IT) (107.95 KB - PDF)

**First published:**

06/09/2022

[View](/it/documents/overview/roctavian-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (138.37 KB - PDF)

**First published:**

06/09/2022

[View](/lv/documents/overview/roctavian-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (131.88 KB - PDF)

**First published:**

06/09/2022

[View](/lt/documents/overview/roctavian-epar-medicine-overview_lt.pdf)

magyar (HU) (133.22 KB - PDF)

**First published:**

06/09/2022

[View](/hu/documents/overview/roctavian-epar-medicine-overview_hu.pdf)

Malti (MT) (134.58 KB - PDF)

**First published:**

06/09/2022

[View](/mt/documents/overview/roctavian-epar-medicine-overview_mt.pdf)

Nederlands (NL) (108.94 KB - PDF)

**First published:**

06/09/2022

[View](/nl/documents/overview/roctavian-epar-medicine-overview_nl.pdf)

polski (PL) (134.54 KB - PDF)

**First published:**

06/09/2022

[View](/pl/documents/overview/roctavian-epar-medicine-overview_pl.pdf)

português (PT) (109.81 KB - PDF)

**First published:**

06/09/2022

[View](/pt/documents/overview/roctavian-epar-medicine-overview_pt.pdf)

română (RO) (131.78 KB - PDF)

**First published:**

06/09/2022

[View](/ro/documents/overview/roctavian-epar-medicine-overview_ro.pdf)

slovenčina (SK) (131.15 KB - PDF)

**First published:**

06/09/2022

[View](/sk/documents/overview/roctavian-epar-medicine-overview_sk.pdf)

slovenščina (SL) (131.23 KB - PDF)

**First published:**

06/09/2022

[View](/sl/documents/overview/roctavian-epar-medicine-overview_sl.pdf)

Suomi (FI) (106.47 KB - PDF)

**First published:**

06/09/2022

[View](/fi/documents/overview/roctavian-epar-medicine-overview_fi.pdf)

svenska (SV) (107.45 KB - PDF)

**First published:**

06/09/2022

[View](/sv/documents/overview/roctavian-epar-medicine-overview_sv.pdf)

Roctavian : EPAR - Risk management plan

English (EN) (61.38 MB - PDF)

**First published:** 06/09/2022

**Last updated:** 28/10/2025

[View](/en/documents/rmp/roctavian-epar-risk-management-plan_en.pdf)

## Product information

Roctavian : EPAR - Product Information

English (EN) (447.89 KB - PDF)

**First published:** 06/09/2022

**Last updated:** 11/11/2025

[View](/en/documents/product-information/roctavian-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-740)

български (BG) (579.56 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/bg/documents/product-information/roctavian-epar-product-information_bg.pdf)

español (ES) (409.29 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/es/documents/product-information/roctavian-epar-product-information_es.pdf)

čeština (CS) (572.6 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/cs/documents/product-information/roctavian-epar-product-information_cs.pdf)

dansk (DA) (437.52 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/da/documents/product-information/roctavian-epar-product-information_da.pdf)

Deutsch (DE) (441.83 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/de/documents/product-information/roctavian-epar-product-information_de.pdf)

eesti keel (ET) (428.37 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/et/documents/product-information/roctavian-epar-product-information_et.pdf)

ελληνικά (EL) (570.92 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/el/documents/product-information/roctavian-epar-product-information_el.pdf)

français (FR) (540.69 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/fr/documents/product-information/roctavian-epar-product-information_fr.pdf)

hrvatski (HR) (520.1 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/hr/documents/product-information/roctavian-epar-product-information_hr.pdf)

íslenska (IS) (427.4 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/is/documents/product-information/roctavian-epar-product-information_is.pdf)

italiano (IT) (502.5 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/it/documents/product-information/roctavian-epar-product-information_it.pdf)

latviešu valoda (LV) (549.94 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/lv/documents/product-information/roctavian-epar-product-information_lv.pdf)

lietuvių kalba (LT) (501.48 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/lt/documents/product-information/roctavian-epar-product-information_lt.pdf)

magyar (HU) (522.59 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/hu/documents/product-information/roctavian-epar-product-information_hu.pdf)

Malti (MT) (604.29 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/mt/documents/product-information/roctavian-epar-product-information_mt.pdf)

Nederlands (NL) (409.95 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/nl/documents/product-information/roctavian-epar-product-information_nl.pdf)

norsk (NO) (439.98 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/no/documents/product-information/roctavian-epar-product-information_no.pdf)

polski (PL) (568.87 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/pl/documents/product-information/roctavian-epar-product-information_pl.pdf)

português (PT) (449.32 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/pt/documents/product-information/roctavian-epar-product-information_pt.pdf)

română (RO) (555 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/ro/documents/product-information/roctavian-epar-product-information_ro.pdf)

slovenčina (SK) (575.11 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/sk/documents/product-information/roctavian-epar-product-information_sk.pdf)

slovenščina (SL) (500.88 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/sl/documents/product-information/roctavian-epar-product-information_sl.pdf)

Suomi (FI) (442.49 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/fi/documents/product-information/roctavian-epar-product-information_fi.pdf)

svenska (SV) (424.04 KB - PDF)

**First published:**

06/09/2022

**Last updated:**

11/11/2025

[View](/sv/documents/product-information/roctavian-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000309039 11/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Roctavian : EPAR - All authorised presentations

English (EN) (40.62 KB - PDF)

**First published:** 06/09/2022

[View](/en/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-443)

български (BG) (90.31 KB - PDF)

**First published:**

06/09/2022

[View](/bg/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_bg.pdf)

español (ES) (11.5 KB - PDF)

**First published:**

06/09/2022

[View](/es/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_es.pdf)

čeština (CS) (93.06 KB - PDF)

**First published:**

06/09/2022

[View](/cs/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (11.37 KB - PDF)

**First published:**

06/09/2022

[View](/da/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (11.35 KB - PDF)

**First published:**

06/09/2022

[View](/de/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (11.34 KB - PDF)

**First published:**

06/09/2022

[View](/et/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (84.01 KB - PDF)

**First published:**

06/09/2022

[View](/el/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_el.pdf)

français (FR) (11.13 KB - PDF)

**First published:**

06/09/2022

[View](/fr/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (90.57 KB - PDF)

**First published:**

06/09/2022

[View](/hr/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (11.21 KB - PDF)

**First published:**

06/09/2022

[View](/is/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_is.pdf)

italiano (IT) (11.16 KB - PDF)

**First published:**

06/09/2022

[View](/it/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (91.7 KB - PDF)

**First published:**

06/09/2022

[View](/lv/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (91.12 KB - PDF)

**First published:**

06/09/2022

[View](/lt/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (45.48 KB - PDF)

**First published:**

06/09/2022

[View](/hu/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (94.59 KB - PDF)

**First published:**

06/09/2022

[View](/mt/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (11.06 KB - PDF)

**First published:**

06/09/2022

[View](/nl/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (11.35 KB - PDF)

**First published:**

06/09/2022

[View](/no/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_no.pdf)

polski (PL) (92.76 KB - PDF)

**First published:**

06/09/2022

[View](/pl/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_pl.pdf)

português (PT) (11.42 KB - PDF)

**First published:**

06/09/2022

[View](/pt/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_pt.pdf)

română (RO) (89.68 KB - PDF)

**First published:**

06/09/2022

[View](/ro/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (93.51 KB - PDF)

**First published:**

06/09/2022

[View](/sk/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (42.56 KB - PDF)

**First published:**

06/09/2022

[View](/sl/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (11.06 KB - PDF)

**First published:**

06/09/2022

[View](/fi/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (11.35 KB - PDF)

**First published:**

06/09/2022

[View](/sv/documents/all-authorised-presentations/roctavian-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Roctavian Active substance valoctocogene roxaparvovec International non-proprietary name (INN) or common name valoctocogene roxaparvovec Anatomical therapeutic chemical (ATC) code B02BD15

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Treatment of severe haemophilia A (congenital factor VIII deficiency) in adult patients without a history of factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5).

## Authorisation details

EMA product number EMEA/H/C/005830

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

BioMarin International Limited

Shanbally

Opinion adopted 23/06/2022 Marketing authorisation issued 24/08/2022 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Roctavian : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (147.28 KB - PDF)

**First published:** 28/10/2025

**Last updated:** 11/11/2025

[View](/en/documents/procedural-steps-after/roctavian-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Roctavian : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (169.55 KB - PDF)

**First published:** 09/11/2022

**Last updated:** 28/10/2025

[View](/en/documents/procedural-steps-after/roctavian-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Roctavian : EPAR - Orphan Maintenance Assessment Report

Adopted

English (EN) (877.88 KB - PDF)

**First published:** 28/09/2022

[View](/en/documents/orphan-maintenance-report/roctavian-epar-orphan-maintenance-assessment-report_en.pdf)

Roctavian : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/685615/2022

English (EN) (4.17 MB - PDF)

**First published:** 06/09/2022

[View](/en/documents/assessment-report/roctavian-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Roctavian

Adopted

Reference Number: EMA/CHMP/584501/2022

English (EN) (137.31 KB - PDF)

**First published:** 24/06/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-roctavian_en.pdf)

#### News on Roctavian

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2022) 24/06/2022

[First gene therapy to treat severe haemophilia A](/en/news/first-gene-therapy-treat-severe-haemophilia) 24/06/2022

#### More information on Roctavian

- [EU/3/16/1622 - orphan designation for treatment of haemophilia A](/en/medicines/human/orphan-designations/eu-3-16-1622)
- [GENEr8-COAS: A Non-Interventional, Multi-National, Longitudinal Study of Patients Treated with ROCTAVIAN™ (valoctocogene roxaparvovec) (GENEr8-COAS Observational Cohort Study) - post-authorisation study](https://catalogues.ema.europa.eu/study/49072)
- [GENEr8-GTR: A Retrospective Cohort Study of Patients Treated with ROCTAVIAN™ (valoctocogene roxaparvovec): An Analysis of Patient Registries (BMN 270-801) - post-authorisation study](https://catalogues.ema.europa.eu/study/49244)

**This page was last updated on** 11/11/2025

## Share this page

[Back to top](#main-content)